Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- 30 April 2011
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (4), 361-368
- https://doi.org/10.1016/s1470-2045(11)70062-6
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia, 2010
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II ConsortiumJournal of Clinical Oncology, 2010
- Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaBritish Journal of Haematology, 2010
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Blood, 2009
- Phase II trial of temsirolimus in patients with relapsed or refractory multiple myelomaLeukemia Research, 2009
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell LymphocytosisLeukemia & Lymphoma, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000